- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03325231
Factors Influencing Patient Choice of Bladder Reconstruction Following Radical Cystectomy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Aims and Objectives. The proposed research aims: firstly, to enhance our understanding of patient concerns, lifestyles, and values, that influence their choice of bladder reconstruction and predict their treatment satisfaction and quality of life (QoL); and, secondly, to initiate the development a novel decision-aid tool to help bladder-cancer patients, their families, and medical/health professionals to choose the reconstructive surgery following bladder removal that best suits a patient's needs. To these ends, a complementary combination of qualitative and quantitative research approaches will be employed to obtain information from patients about the reasons for their reconstructive surgery choices, the aspects of their lifestyle that were most important to them in reaching their decisions, and the degree to which they are satisfied with their reconstruction. These findings will be used to inform the items to be contained in a pilot joint decision-making tool to support patients and medical professionals when planning such life-changing surgery. Such a tool ultimately could support patient choice, enhance QoL, and influence decision-making practice. Thus, the specific objectives of the research will be to: (1) identify the factors important for patients when choosing a bladder reconstruction; (2) establish the degree to which these factors predict satisfaction with the reconstruction; and, ultimately, (3) start to develop a joint decision-aid tool for patients and medical staff, to use when deciding on the choice of diversionary procedure, that highlights these key factors predicting success and better QoL following different forms of bladder reconstruction.
Methodology and Project Plan. Participants Participants will be recruited from Health Board databases of those who have had advanced bladder cancer (grade pT1 and above) and undergone either IC or NB procedures within the last five years. Around 40 patients per year are referred to the ABMU; this is in line with expectations, given the size of the ABMU patient population (600,000) and rates of bladder cancer, giving a potential sample of 200 patients over the previous five years. This will provide an adequate population from which to sample participants. No form of payment will be offered for participation, but participants will be reimbursed for travel expenses. There will be no other inclusion or exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
Qualitative Study Forty participants (equal numbers with each surgical procedure) will be randomly selected from the patient databases and invited for interview. This number is achievable given the size of the database, and exceeds the usual criteria (12-18; Guest et al., 2006) for saturation in qualitative research, even with expectation of some non-participation.
The participants will be interviewed by a Researcher and a Clinical Nurse Specialist in a quiet room in the Clinical Research Unit of the Hospital. A semi-structured interview format will be adopted to allow participants latitude in expressing issues that are important to them, and without forcing particular issues. The same semi-structured interview script will be used for each participant, ensuring all are asked the same questions. The general themes to be asked about will be: Who patients consulted and discussed options with; What types of information, support, and advice were they offered; What were the attributes or aspects of the NB/IC that influenced their choice; Which aspects of their lifestyle were most important in making a decision; What factors could have been considered that were not; What types of help have they been offered since; Could they have been offered other information at the time; How do they feel their choice influences their life today; Are they satisfied with their decision. These questions will allow a wide range of patient needs, values, and experiences to be elicited.
Transcribed interview recordings will be subjected to thematic content analysis, in line with previous recommendations (Vaughn et al., 1996), and accepted procedures in health contexts (Osborne et al., 2012a; 2012b; Osborne & Reed, 2008). Transcripts will be examined independently by two Researchers to identify key themes and ensure reliability. Individual 'units of information' contained within each transcript will be highlighted (a 'unit' is any piece of text that relates to an identified theme, and that can be interpreted on its own to provide a meaningful and informative comment). From reading the unitised comments, the initial themes will be refined, so that all 'units of information' can be categorised according to those themes. Coding of 'units' into themes will be conducted independently by two Researchers, and Cohen's Kappa will be used to establish reliability.
Quantitative Study One hundred participants (equal numbers with IC and NB) will be randomly selected from the Health Board database, as described above. The numbers in the database (200) will allow recruitment of these participants, and, assuming a 50% non-return rate, this will allow sufficient power for subsequent analyses. G-Power calculations suggest that, to identify a moderate relationship (r = .3) with 85% power, a sample size of 90 will be needed. If recruitment appears to be low, then other health boards (in particular, Newcastle with whom Mr. Younis is currently employed) will be approached.
Participants will be asked to complete three questionnaires and to return them using a prepaid envelope. Participants will be provided with contact details of a Clinical Nurse Specialist known to them if they require help completing three questionnaires: Bladder Reconstruction Satisfaction Questionnaire measures levels of satisfaction with bladder reconstruction, the relative ease of adapting to the new bladder, and specific aspects patients are happy or unhappy with regarding their procedure; EORTC QLQ-30 (Aaronson et al., 1993) assesses QoL aspects relevant to cancer patients concerning: physical functioning; role functioning; emotional functioning; cognitive functioning; social functioning; and global health status. This questionnaire is reliable and has been used by a large number of researchers (Mystakidou et al., 2001); The Life Values Inventory (Crace & Brown, 1996) measures values across: achievement, belonging, concern for the environment, concern for others, creativity, financial prosperity, health and activity, humility, independence, loyalty to family or group, privacy, responsibility, scientific understanding, and spirituality. The internal reliability is high (Cheng & Fleischmann, 2010).
The values identified will be related by regression analyses to QoL and satisfaction in order to identify whether there are different predictors of outcome for different forms of bladder reconstruction.
Pilot Tool Development Converging themes emerging from the two studies in terms of predicting satisfaction with IC and NB will be drawn together, and a decision-aid tool will be produced for future study. The items identified for inclusion in the tool will be sent to a range of health professionals involved in delivery of surgery and physiotherapy (consultant surgeons, registrars, clinical nurse specialists, and past patients) to obtain their views on its face validity. Items that are rated as inappropriate or redundant will be re-assessed and potentially excluded from the tool, and any missing areas of importance identified by the expert panel will be re-examined.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Swansea, United Kingdom, SA2 8PP
- Professor Phil Reed
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Participants will be recruited from those who have had advanced bladder cancer (grade pT1 and above) and undergone either ileal conduit (IC) or neobladder (NB) procedures within the last five years. There will be no other inclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
Exclusion Criteria:
- Anybody under the age of 18 years will be excluded. Apart from this, there will be no exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Bladder Cancer Patients
Participants will be recruited from those who have had advanced bladder cancer (grade pT1 and above) and undergone either IC or NB procedures within the last five years.
No form of payment will be offered for participation, but participants will be reimbursed for travel expenses.
There will be no other inclusion or exclusion criteria in order to access a wide range of patients with potentially different values and lifestyles, and to aid in the recruitment of adequate sample sizes.
|
Investigating patient experience of bladder reconstructions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Bladder Reconstruction Satisfaction Questionnaire
Time Frame: 2 Years
|
2 Years
|
EORTC QLQ-30
Time Frame: 2 Years
|
2 Years
|
The Life Values Inventory
Time Frame: 2 Years
|
2 Years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RIO 018-17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
Clinical Trials on Reconstructive surgery following bladder removal.
-
Helsinki University Central HospitalCompletedReconstructive Surgical ProcedureFinland
-
Helsinki University Central HospitalUniversity of Helsinki; University of Eastern FinlandCompleted
-
Universiteit AntwerpenRecruitingOveractive Bladder | Voiding Disorders | Pelvic Organ Prolapse | Stress Urinary Incontinence | Urge IncontinenceBelgium
-
Yonsei UniversityRecruiting
-
TriHealth Inc.CompletedPelvic Organ Prolapse | Same Day Discharge | Total Vaginal HysterectomyUnited States
-
Peking Union Medical College HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; LinkDoc... and other collaboratorsUnknownPelvic Organ ProlapseChina
-
Peking Union Medical College HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; LinkDoc... and other collaboratorsUnknown
-
Postgraduate Institute of Dental Sciences RohtakUnknown
-
Universitaire Ziekenhuizen KU LeuvenRecruitingLymphedema | Lymphedema Arm | Lymphoedema of LegBelgium
-
M.D. Anderson Cancer CenterCompletedMammoplasty PatientUnited States